Plain-English translation of NCT06307652 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing balcinrenone combined with dapagliflozin against dapagliflozin alone in people with heart failure and reduced kidney function. The study wants to see if adding this medication to current treatment helps prevent hospitalizations, worsening heart failure, and heart-related death. About 4,800 people will participate across 700 hospitals worldwide.
People with heart failure and kidney problems have limited treatment options and face high risks of serious complications. Researchers believe this medication combination may offer better protection for both the heart and kidneys than current treatments alone.
You likely qualify if…
You likely don't qualify if…
You would take one capsule and one tablet by mouth once daily for about 20 months, with regular clinic visits to check your heart health, kidney function, and blood pressure. You'll be randomly assigned to receive one of three treatment combinations, and neither you nor your doctors will know which one you're taking until the study ends. The entire study participation, including screening and follow-up, typically lasts about 22 months.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States